Dalantercept
The TGF-b superfamily receptor activin receptor-like kinase 1 (ALK-1) has essential roles in regulating angiogenesis during development and homeostasis, as well as pathophysiological tumor angiogenesis. Dalantercept is a soluble chimeric protein composed of the ALK-1 extracellular domain fused to the human Fc domain. Dalantercept acts as a ligand trap to prevent the activation of endogenous ALK-1 by bone morphogenetic proteins 9/10. In preclinical models, dalantercept inhibits tumor growth and enhances the efficacy of cytotoxic chemotherapy. In early clinical development, dalantercept as a single agent has had a promising disease control rate. Dalantercept has a favorable safety profile, with fluid retention and edema being the most common side effects. Current studies are investigating the role of dalantercept with cytotoxic chemotherapy and other targeted therapies.
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Medicinal & Biomolecular Chemistry
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Medicinal & Biomolecular Chemistry
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences